Urgent.News

What's breaking now, across thousands of outlets.

Science

An experimental treatment improves the cognitive ability and gut microbiota of mice with fragile X syndrome

Ongoing treatment with a drug that inhibits the endocannabinoid system peripherally improves memory deficits, reduces synaptic alterations, mitigates gut microbiota dysbiosis and restores intestinal barrier integrity markers in fragile X syndrome mouse models. This experimental approach opens the door to studying a potential therapy to improve the cognitive ability of people who have the syndrome…

An experimental treatment improves the cognitive ability and gut microbiota of mice with fragile X syndrome

A one-week experimental treatment targeting peripheral cannabinoid receptors in mice with fragile X syndrome has shown promising results. The treatment enhanced memory and synaptic alterations, while also improving gut microbiota dysbiosis and restoring intestinal barrier integrity. Fragile X syndrome, the most common monogenic cause of intellectual disability and autism spectrum disorder, affects around 10,000 people in Spain, with 127,000 carriers in total.

The study, conducted by researchers at Pompeu Fabra University, suggests that a peripheral pharmacological approach could potentially improve the cognitive abilities and gut health of individuals with fragile X syndrome. Further research is needed to determine the effects of this treatment in humans and the role of intestinal CB1 receptors.

Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at medicalxpress.com →

More in Science

More from Thursday 19 November →